Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6751579 | 0.84 | ALDH1A1 (0.35) | MAPTHTTNPC1RAB9AHPGD | |
| SCHEMBL27430125 | 0.78 | MAPT (0.43) | MAPTHTTNPC1RAB9AHPGD | |
| SCHEMBL27487769 | 0.73 | MAPT (0.46) | MAPTHTTRAB9AHPGDALDH1A1 | |
| SCHEMBL6851021 | 0.73 | ALDH1A1 (0.46) | MAPTHTTNPC1RAB9AHPGD | |
| SCHEMBL6854905 | 0.73 | SMN1; SMN2 (0.45) | NPC1RAB9AHPGDALDH1A1GAA | |
| SCHEMBL6857887 | 0.73 | TSHR (0.45) | MAPTHTTNPC1RAB9AHPGD | |
| SCHEMBL7073375 | 0.73 | — | — | |
| SCHEMBL6851229 | 0.73 | SIGMAR1 (0.39) | — | |
| SCHEMBL9355162 | 0.73 | GAA (0.62) | MAPTHTTNPC1RAB9AHPGD | |
| SCHEMBL29511793 | 0.73 | HTT (0.59) | MAPTHTTNPC1RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101549597-B | Relief printing plate precursor for laser engraving, relief printing plate, and method of manufacturing relief printing plate | FUJI PHOTO FILM CO LTD | 2013-09-18 | — | — | CN | disclosed |
| EP-1060182-B1 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS INC (US) | 2012-12-19 | — | — | EP | disclosed |
| CN-101549597-A | Relief printing plate precursor for laser engraving, relief printing plate, and method of manufacturing relief printing plate | FUJIFILM CORP (JP) | 2009-10-07 | — | — | CN | disclosed |
| CN-101398622-A | Method of producing a negative planographic printing plate | FUJIFILM CORP (JP) | 2009-04-01 | — | — | CN | disclosed |
| US-7351399-B2 | Prodrugs for phosphorus-containing compounds | METABASIS THERAPEUTICS, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-20050288240-A1 | Novel-prodrugs for phosphorus-containing compounds | ERION MARK D | 2005-12-29 | — | — | US | disclosed |
| EP-1427408-A4 | CYCLIC HYDROXAMIC ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-$g(a) CONVERTING ENZYME (TACE) | BRISTOL MYERS SQUIBB CO (US) | 2005-10-26 | — | — | EP | disclosed |
| US-6946115-B2 | Prodrugs for phosphorus-containing compounds | METABASIS THERAPEUTICS, INC. (US) | 2005-09-20 | — | — | US | disclosed |
| EP-1427408-A2 | CYCLIC HYDROXAMIC ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-$g(a) CONVERTING ENZYME (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-16 | — | — | EP | disclosed |
| US-6740649-B2 | ANTIINFLAMMATORY AGENTS; OSTEOPOROSIS | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-25 | — | — | US | disclosed |
| US-6312662-B1 | CONVERSION BY HUMAN LIVER MICROSOMES TO MPO3H2 | METABASIS THERAPEUTICS, INC. | 2001-11-06 | — | — | US | disclosed |
| US-6294672-B1 | FOR THERAPY OF DIABETES, AND OTHER DISEASES WHERE THE INHIBITION OF GLUCONEOGENESIS, CONTROL OF BLOOD GLUCOSE LEVELS, REDUCTION IN GLYCOGEN STORES, OR REDUCTION IN INSULIN LEVELS IS BENEFICIAL | METABASIS THERAPEUTICS, INC. | 2001-09-25 | — | — | US | disclosed |
| EP-1060182-A2 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | Metabasis Therapeutics, Inc. (US) | 2000-12-20 | — | — | EP | disclosed |
| US-6054587-A | ANTIDIABETIC AGENTS | METABASIS THERAPEUTICS, INC. (US) | 2000-04-25 | — | — | US | disclosed |
| WO-1999045016-A9 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS INC (US) | 2000-03-02 | — | — | WO | disclosed |
| WO-1999045016-A2 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS, INC. (US) | 1999-09-10 | — | — | WO | disclosed |
| WO-1998039342-A1 | NOVEL INDOLE AND AZAINDOLE INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS, INC. (US) | 1998-09-11 | — | — | WO | disclosed |
| US-5599832-A | INDOLES SUBSTITUTED WITH GROUPS BOTH ELECTRON WITHDRAWING AND LIPOPHILIC; GROWING, HARVESTING AND STORAGE OF CROPS | AMERICAN CYANAMID COMPANY (US) | 1997-02-04 | — | — | US | disclosed |
| US-5502071-A | PLANTS | AMERICAN CYANAMID COMPANY (US) | 1996-03-26 | — | — | US | disclosed |
| EP-0697172-A1 | Indoles as insecticides and acaricides | AMERICAN CYANAMID COMPANY (US) | 1996-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288240-A1 | Novel-prodrugs for phosphorus-containing compounds | HCRTR2, CYP2R1, SLC22A8 | MAPT 4762/4885HTT 4642/4885NPC1 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.